Bank of America Cuts Immunovant (NASDAQ:IMVT) Price Target to $45.00
Bank of America reduced their target price on Immunovant from $48.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday.
Source link
Similar Posts
CDK hack ripples through US auto industry as dealers flag hit By Reuters
By Kannaki Deka (Reuters) -More U.S. auto dealers flagged a hit from a cyber attack-led software outage at CDK on Monday as the company worked to restore systems used by more than 15,000 retail locations across North America. The outage impacting CDK’s dealer management system, used to complete deals, track store profitability and monitor employee…
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress – Bio Tech Winners
June 13, 2024 by Leave a Comment Last Updated on June 13, 2024 by [#item_full_content] Like this: Like Loading… Related Filed Under: biotech news, News Reader Interactions This site uses Akismet to reduce spam. Learn how your comment data is processed. Source link
Question #8 for 2026: How much will Residential investment change in 2026? How about housing starts and new home sales in 2026?
Earlier I posted some questions on my blog for next year: Ten Economic Questions for 2026. Some of these questions concern real estate (inventory, house prices, housing starts, new home sales), and I’ll post thoughts on those in this newsletter (others like GDP and employment will be on my blog). I’m adding some thoughts, and…
Top Canadian Stocks to Buy Right Now With $2,000
Investing in equity markets with a long-term perspective is an effective way to grow wealth, keep pace with inflation, and ride out short-term market ups and downs. Notably, stocks have historically delivered higher returns than most other asset classes in the long run, helping investors build meaningful capital to support their future financial goals. With…
Why Air Products & Chemicals Deserves A Spot In Your Portfolio (NYSE:APD)
aluxum/E+ via Getty Images Introduction On August 30, I wrote an article titled “Dividend Kings Are Overrated.” In that article, I explained that although dividend consistency is a great thing, dividend stocks should never be selected based on Dividend Aristocrat or Dividend King status. That said, there are plenty of good Dividend Aristocrats on the…
Business News Live, Share Market News – Read Latest Finance News, IPO, Mutual Funds News – The Economic Times
Despite weak broader markets and rising geopolitical tensions, select smallcap stocks delivered sharp gains this week, with some surging over 40%. The rally highlights pockets of strength in sectors like chemicals, energy, and industrials, even as inflation concerns and global uncertainties continue to weigh on overall market sentiment. Source link
